Taylor Wessing

Comment: This firm highly recommended for M&A has one of the biggest small- to mid-cap practices in the market, rivaling competitors such as Noerr and CMS in this segment. The utilization rate was particularly high over the past year with a gradual but perceptible increase in deal size. The permanent breakthrough on a broad scale into the large-cap sector still evades the firm, however, even though it has a relatively large number partners in its ranks who were at leading corporate practices such as Clifford Chance, Linklaters or Skadden. Encouraging is the more intensive integration both with other practices areas – leading to referrals from non-transactional areas, in particular amongst technology clients. The string of deals for DaVita in medical technology was the best example, but the establishment of the office in Silicon Valley has also improved deal flow out of the US. Since TW is one of the firm’s in the market with a particularly strong sector focus, the loss of the energy team in Berlin, and transaction specialist Dr. Thomas Dörmer in particular was a disappointing development.
Strengths: Strong transaction practice in Düsseldorf and Hamburg. ?Media, ?pharmaceuticals and healthcare and renewable ?energies. German-Chinese transactions.
Development potential: The recruitment of associates remains a high priority for the practice: the high partner involvement is on the one hand necessary for Mittelstand-oriented transactions, but larger deals would produce too much work for the already overworked partners. In addition, while integration with other TW offices is improving it still remains behind the market standard set by other international firms.
Recommended: Dr. Peter Hellich (“incredibly hard-working, very service-focused”, competitor), Dr. Ernst-Albrecht von Beauvais, Dr. Klaus Grossmann (“closes virtually every deal”, competitor), Robert Wethmar, Dr. Frank Koch (“strong duo in Hamburg, sometimes underestimated”, competitor), Hassan Sohbi, Dr. Carsten Bartholl, Dr. Walter Henle, Dr. Oliver Kirschner.
Practice: Focus on the technology, media, biotech, life sciences, medical technology, financial services and real estate sectors, predominantly in midsized deals. Chinese practice in Munich, increasingly active for Chinese companies in Germany. Inbound work from the US. (Corporate in total: 45 equity partners, 8 salary partners, 23 associates)
Clients: ?? Saint-Gobain on acquisition of Kirson Industrial Reinforcements; DaVita on acquisition of various dialysis units to develop Germany-wide network; Amri Inc. on acquisition of Euticals; Rewe on acquisition of several Kaiser’s Tengelmann branches from Edeka and on takeover of majority stake in Supermärkte Nord Vertrieb through secondary offering; Pfeiffer Intercontec shareholder on sale to TE Connectivity.
  • Teilen